|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mittal D, Gubin MM, Schreiber RD and Smyth
MJ: New insights into cancer immunoediting and its three component
phases-elimination, equilibrium and escape. Curr Opin Immunol.
27:16–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vesely MD, Kershaw MH, Schreiber RD and
Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev
Immunol. 29:235–271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M,
Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, et al: Overexpression
of PD-L1 significantly associates with tumor aggressiveness and
postoperative recurrence in human hepatocellular carcinoma. Clin
Cancer Res. 15:971–979. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding
ZB, Devbhandari RP, Huang XY, Qiu SJ, Shi YH, et al: CD151
modulates expression of matrix metalloproteinase 9 and promotes
neoangiogenesis and progression of hepatocellular carcinoma.
Hepatology. 52:183–196. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thomas DA and Massagué J: TGF-beta
directly targets cytotoxic T cell functions during tumor evasion of
immune surveillance. Cancer Cell. 8:369–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Borsellino G, Kleinewietfeld M, Di Mitri
D, Sternjak A, Diamantini A, Giometto R, Höpner S, Centonze D,
Bernardi G, Dell'Acqua ML, et al: Expression of ectonucleotidase
CD39 by FoxP3+ Treg cells: Hydrolysis of extracellular
ATP and immune suppression. Blood. 110:1225–1232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dwyer KM, Deaglio S, Gao W, Friedman D,
Strom TB and Robson SC: CD39 and control of cellular immune
responses. Purinergic Signal. 3:171–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou Q, Yan J, Putheti P, Wu Y, Sun X,
Toxavidis V, Tigges J, Kassam N, Enjyoji K, Robson SC, et al:
Isolated CD39 expression on CD4+ T cells denotes both
regulatory and memory populations. Am J Transplant. 9:2303–2311.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Marcus AJ, Broekman MJ, Drosopoulos JH,
Islam N, Alyonycheva TN, Safier LB, Hajjar KA, Posnett DN,
Schoenborn MA, Schooley KA, et al: The endothelial cell ecto-ADPase
responsible for inhibition of platelet function is CD39. J Clin
Invest. 99:1351–1360. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Plesner L: Ecto-ATPases: Identities and
functions. Int Rev Cytol. 158:141–214. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Enjyoji K, Sévigny J, Lin Y, Frenette PS,
Christie PD, Esch JS II, Imai M, Edelberg JM, Rayburn H, Lech M, et
al: Targeted disruption of cd39/ATP diphosphohydrolase results in
disordered hemostasis and thromboregulation. Nat Med. 5:1010–1017.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pulte ED, Broekman MJ, Olson KE,
Drosopoulos JH, Kizer JR, Islam N and Marcus AJ: CD39/NTPDase-1
activity and expression in normal leukocytes. Thromb Res.
121:309–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leal DB, Streher CA, Neu TN, Bittencourt
FP, Leal CA, da Silva JE, Morsch VM and Schetinger MR:
Characterization of NTPDase (NTPDase1; ecto-apyrase;
Ecto-diphosphohydrolase; CD39; EC 3.6.1.5) activity in human
lymphocytes. Biochim Biophys Acta. 1721:9–15. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun X, Wu Y, Gao W, Enjyoji K, Csizmadia
E, Müller CE, Murakami T and Robson SC: CD39/ENTPD1 expression by
CD4+FoxP3+ regulatory T cells promotes
hepatic metastatic tumor growth in mice. Gastroenterology.
139:1030–1040. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ring S, Oliver SJ, Cronstein BN, Enk AH
and Mahnke K: CD4+CD25+ regulatory T cells
suppress contact hypersensitivity reactions through a CD39,
adenosine-dependent mechanism. J Allergy Clin Immunol.
123:1287–1296.e2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goepfert C, Imai M, Brouard S, Csizmadia
E, Kaczmarek E and Robson SC: CD39 modulates endothelial cell
activation and apoptosis. Mol Med. 6:591–603. 2000.PubMed/NCBI
|
|
19
|
Pulte D, Furman RR, Broekman MJ,
Drosopoulos JH, Ballard HS, Olson KE, Kizer JR and Marcus AJ: CD39
expression on T lymphocytes correlates with severity of disease in
patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma
Leuk. 11:367–372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Künzli BM, Bernlochner MI, Rath S, Käser
S, Csizmadia E, Enjyoji K, Cowan P, d'Apice A, Dwyer K, Rosenberg
R, et al: Impact of CD39 and purinergic signalling on the growth
and metastasis of colorectal cancer. Purinergic Signal. 7:231–241.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Künzli BM, Berberat PO, Giese T, Csizmadia
E, Kaczmarek E, Baker C, Halaceli I, Büchler MW, Friess H and
Robson SC: Upregulation of CD39/NTPDases and P2 receptors in human
pancreatic disease. Am J Physiol Gastrointest Liver Physiol.
292:G223–G230. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Godbout JP and Glaser R: Stress-induced
immune dysregulation: Implications for wound healing, infectious
disease and cancer. J Neuroimmune Pharmacol. 1:421–427. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kono K, Kawaida H, Takahashi A, Sugai H,
Mimura K, Miyagawa N, Omata H and Fujii H:
CD4(+)CD25high regulatory T cells increase with tumor
stage in patients with gastric and esophageal cancers. Cancer
Immunol Immunother. 55:1064–1071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ichihara F, Kono K, Takahashi A, Kawaida
H, Sugai H and Fujii H: Increased populations of regulatory T cells
in peripheral blood and tumor-infiltrating lymphocytes in patients
with gastric and esophageal cancers. Clin Cancer Res. 9:4404–4408.
2003.PubMed/NCBI
|
|
25
|
Perrone G, Ruffini PA, Catalano V, Spino
C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V,
Alessandroni P, et al: Intratumoural FoxP3-positive regulatory T
cells are associated with adverse prognosis in radically resected
gastric cancer. Eur J Cancer. 44:1875–1882. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cai XY, Wang XF, Li J, Dong JN, Liu JQ, Li
NP, Yun B and Xia RL: Overexpression of CD39 and high tumoral
CD39+/CD8+ ratio are associated with adverse
prognosis in resectable gastric cancer. Int J Clin Exp Pathol.
8:14757–14764. 2015.PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kansas GS, Wood GS and Tedder TF:
Expression, distribution, and biochemistry of human CD39. Role in
activation-associated homotypic adhesion of lymphocytes. J Immunol.
146:2235–2244. 1991.PubMed/NCBI
|
|
29
|
Favaloro EJ: Differential expression of
surface antigens on activated endothelium. Immunol Cell Biol.
71:571–581. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dwyer KM, Hanidziar D, Putheti P, Hill PA,
Pommey S, McRae JL, Winterhalter A, Doherty G, Deaglio S, Koulmanda
M, et al: Expression of CD39 by human peripheral blood
CD4+ CD25+ T cells denotes a regulatory
memory phenotype. Am J Transplant. 10:2410–2420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rissiek A, Baumann I, Cuapio A, Mautner A,
Kolster M, Arck PC, Dodge-Khatami A, Mittrücker HW, Koch-Nolte F,
Haag F and Tolosa E: The expression of CD39 on regulatory T cells
is genetically driven and further upregulated at sites of
inflammation. J Autoimmun. 58:12–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deaglio S, Dwyer KM, Gao W, Friedman D,
Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, et al:
Adenosine generation catalyzed by CD39 and CD73 expressed on
regulatory T cells mediates immune suppression. J Exp Med.
204:1257–1265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ohta A, Kini R, Ohta A, Subramanian M,
Madasu M and Sitkovsky M: The development and immunosuppressive
functions of CD4(+) CD25(+)
FoxP3(+) regulatory T cells are under influence of the
adenosine-A2A adenosine receptor pathway. Front Immunol. 3:1902012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schuler PJ, Saze Z, Hong CS, Muller L,
Gillespie DG, Cheng D, Harasymczuk M, Mandapathil M, Lang S,
Jackson EK and Whiteside TL: Human CD4+ CD39+
regulatory T cells produce adenosine upon co-expression of surface
CD73 or contact with CD73+ exosomes or CD73+
cells. Clin Exp Immunol. 177:531–543. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang H, Xu R, Lin F, Bao C, Wang S, Ji C,
Li K, Jin L, Mu J, Wang Y, et al: High circulating
CD39(+) regulatory T cells predict poor survival for
sepsis patients. Int J Infect Dis. 30:57–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang HY, Yan KX, Huang Q, Ma Y, Fang X
and Han L: Target tissue ectoenzyme CD39/CD73-expressing
FoxP3+ regulatory T cells in patients with psoriasis.
Clin Exp Dermatol. 40:182–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hilchey SP, Kobie JJ, Cochran MR,
Secor-Socha S, Wang JC, Hyrien O, Burack WR, Mosmann TR, Quataert
SA and Bernstein SH: Human follicular lymphoma
CD39+-infiltrating T cells contribute to
adenosine-mediated T cell hyporesponsiveness. J Immunol.
183:6157–6166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Mandapathil M, Lang S, Gorelik E and
Whiteside TL: Isolation of functional human regulatory T cells
(Treg) from the peripheral blood based on the CD39 expression. J
Immunol Methods. 346:55–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
